Trial Profile
A Randomized Phase II, Placebo-controlled, Multicenter Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 24 Nov 2023
Price :
$35
*
At a glance
- Drugs Regorafenib (Primary)
- Indications Chondrosarcoma; Chordoma; Ewing's sarcoma; Osteosarcoma
- Focus Therapeutic Use
- Acronyms REGOBONE
- 01 Nov 2023 Primary endpoint has not been met, (Non-progression rate), as per Results published in the British Journal of Cancer
- 01 Nov 2023 Results published in the British Journal of Cancer
- 01 Apr 2022 Planned End Date changed from 1 Mar 2023 to 1 Mar 2026.